{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:37Z","timestamp":1793262937758,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jiac.2026.103097","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:44:44Z","timestamp":1791243884000},"page":"103097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti\u2013receptor-binding domain IgG responses after SARS-CoV-2 infection in outpatients treated with ensitrelvir"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-8463","authenticated-orcid":false,"given":"Naoki","family":"Tani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4229-7945","authenticated-orcid":false,"given":"Tomonori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4150-1583","authenticated-orcid":false,"given":"Naoki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-4231","authenticated-orcid":false,"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103097_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkad027","article-title":"Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo","volume":"78","author":"Kuroda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103097_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-Day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.jiac.2026.103097_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of Ensitrelvir, a novel oral SARS-CoV-2 3C-Like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2026.103097_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102852","article-title":"Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period","volume":"31","author":"Kawai","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103097_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after Nirmatrelvir\u2013ritonavir treatment","volume":"387","author":"Charness","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103097_bib6","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19)","volume":"76","author":"Boucau","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2026.103097_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1473-3099(25)00482-7","article-title":"Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"26","author":"Schilling","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2026.103097_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102842","article-title":"Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination","volume":"31","author":"Goto","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103097_bib9","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1016\/j.vaccine.2023.10.035","article-title":"Distinct features of SARS-CoV-2 humoral immunity against omicron breakthrough infection","volume":"41","author":"Goto","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2026.103097_bib10","first-page":"1235","article-title":"Use of coefficient of variation in assessing variability of quantitative assays","volume":"9","author":"Reed","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jiac.2026.103097_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following Nirmatrelvir\/Ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2026.103097_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad625","article-title":"Association of Nirmatrelvir\/Ritonavir treatment and COVID-19-Neutralizing antibody titers in a longitudinal health care worker cohort","volume":"11","author":"Decker","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2026.103097_bib13","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3390\/microorganisms11102607","article-title":"Does Nirmatrelvir\/Ritonavir influence the immune response against SARS-CoV-2, independently from rebound?","volume":"11","author":"Panza","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.jiac.2026.103097_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41467-021-21856-3","article-title":"T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses","volume":"12","author":"Ogbe","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2026.103097_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jiac.2026.103097_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:51Z","timestamp":1793261511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1341321X26001959"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103097","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013receptor-binding domain IgG responses after SARS-CoV-2 infection in outpatients treated with ensitrelvir","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103097"}}